Published in Gene Therapy Weekly, January 9th, 2003
Researchers at Children's Hospital Boston, which is affiliated with Harvard Medical School, have studied such antagonists in mouse leukemia models. Their data suggest agents that can selectively block vascular endothelial growth factor (VEGF) activity would stop acute myeloid leukemia in its tracks.
"Recent studies on patients with acute myeloid leukemia (AML) showed increased levels of leukocyte-associated VEGF and neovascularization of the bone marrow," commented Gunter Schuch and colleagues in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.